Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series
Internal and Emergency Medicine · 2024
DOI: 10.1007/s11739-024-03690-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Grzegorz Sokołowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Endocrinology, Jagiellonian University Medical College, ul. Jakubowskiego 2, 30-688, Kraków, Poland. Hauptthemen laut MEDLINE: COVID-19, Myxedema, Coma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The COVID-19 pandemic was a major challenge for all health care employees, but it was also difficult for patients to gain access to health care services. Myxedema coma (MC) is an extremely rare but potentially fatal endocrine emergency. The aim of the study was to report an increased incidence of life-threatening myxedema coma that occurred in relation to the COVID-19 pandemic. In this paper, we report a cohort of 11 patients with MC who were treated at the University Hospital in Krakow, Poland, in the period from 2015 to 2023. Only 1 case of MC was recorded in the period from 2015 to 2019, and, in the same area, 10 cases of MC were recorded after the start of COVID-19 pandemic until present. Hypothyroidism was diagnosed de novo in 2 (18%) patients; the remaining patients were severely hypothyroid due to therapy non-compliance. Nine patients had primary hypothyroidism, and 2 had central hypothyroidism. Besides longstanding hypothyroidism, an additional precipitating factor for MC was identified in 4 (36%) of the patients. Due to the inaccessibility of parenteral levothyroxine, patients were treated with oral, mostly liquid, form of levothyroxine. The mortality rate in this cohort was 27.2%. In conclusion, the increase of the incidence of MC, which is a life-threatening complication of inadequately treated hypothyroidism, during the COVID-19 pandemic, when resources were limited, and in the post-pandemic era, underlines the importance of adequate communication with patients and of long-term availability of primary care for patients with thyroid disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chair and Department of Endocrinology, Jagiellonian University Medical College, ul. Jakubowskiego 2, 30-688, Kraków, Poland.
- Faculty of Medicine, Department of Internal Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Department of Nuclear Medicine, University Medical Centre, Ljubljana, Slovenia.
- Department of Endocrinology, Oncological Endocrinology, Nuclear Medicine and Internal Medicine, University Hospital, Kraków, Poland.
- Chair and Department of Endocrinology, Jagiellonian University Medical College, ul. Jakubowskiego 2, 30-688, Kraków, Poland. alicja.hubalewska-dydejczyk@uj.edu.pl.
ORCID-Profile: Alicja Hubalewska-Dydejczyk
Zitieren
APA
Sokołowski, G., Studen, K. B., Opalinska, M., Wegrzyn, K., Motyka, M., Gilis-Januszewska, A., & Hubalewska-Dydejczyk, A. (2024). Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03690-9
Vancouver
Sokołowski G, Studen KB, Opalinska M, Wegrzyn K, Motyka M, Gilis-Januszewska A, et al. Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series. Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03690-9
BibTeX
@article{Sokoowski2024,
author = {Sokołowski, Grzegorz and Studen, Katica Bajuk and Opalinska, Marta and Wegrzyn, Karolina and Motyka, Marcin and Gilis-Januszewska, Aleksandra and Hubalewska-Dydejczyk, Alicja},
title = {Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series},
journal = {Internal and Emergency Medicine},
year = {2024},
doi = {10.1007/s11739-024-03690-9}
}
EUVIMED